ADAPT-Sepsis试验中生物标志物指导抗生素方案的执行与依从性
该研究是ADAPT-Sepsis试验的预设过程评估,纳入英国41个重症监护单元的2760名成人脓毒症患者,比较降钙素原指导、C反应蛋白指导与标准治疗。降钙素原组强烈建议停药时间更早,但C反应蛋白组总体建议依从性更高,因其标准治疗建议比例更高且更强停药建议的依从性更好。
要点
- 降钙素原组强烈停药建议比C反应蛋白组早1.7天。
- C反应蛋白组标准治疗建议比例更高,总体依从性优于降钙素原组。
- 不依从原因包括固定疗程微生物学指导、病情严重程度、持续发热和常规炎症标志物升高。
核心结论
- C反应蛋白指导的停药方案获得更高的临床医生依从性,可能因其建议更贴近既定处方习惯。
- 降钙素原指导产生更早且更频繁的停药信号,有更大潜力减少抗生素暴露,但需临床医生接受比常规更早停药。
研究设计与样本
- ADAPT-Sepsis试验的嵌入式描述性过程评估,纳入英国41个重症监护单元的2760名成人患者。
- 患者被分配至降钙素原指导组、C反应蛋白指导组或标准治疗组,临床医生对分组设盲。
主要发现
- 降钙素原组强烈停药建议出现时间早于C反应蛋白组,平均差异-1.7天(95%CI -2.5至-0.9,p<0.001)。
- C反应蛋白组标准治疗建议比例更高,平均差异-9.1%(95%CI -10.9%至-7.3%,p<0.001)。
- C反应蛋白组总体建议依从性高于降钙素原组,平均差异-6.8%(95%CI -9.0至-4.5,p<0.001)。
- 更强停药建议的依从性在C反应蛋白组更高,平均差异-14.3%(95%CI -21.8至-6.8,p<0.001)。
- 不依从原因包括固定疗程微生物学指导、病情严重程度、持续发热和常规炎症标志物升高,组间无差异。
关键数值与推荐
- 依从性定义为在建议后停止生物标志物采样。
- 算法生成建议分为强烈停药、建议停药或标准治疗,传达给设盲的研究人员和临床医生。
临床怎么用
- C反应蛋白指导方案可能因更贴合常规实践而更易被临床医生接受。
- 降钙素原指导可提供更早停药信号,但需临床医生愿意接受比常规更早的停药决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Summary Introduction Biomarker-guided antibiotic protocols using daily procalcitonin or C-reactive protein have been proposed to optimise antibiotic duration in sepsis. This pre-planned process evaluation of the ADAPT-Sepsis trial examined delivery and clinician adherence to procalcitonin- and C-reactive protein-guided protocols. Methods An embedded descriptive process evaluation was conducted within the multicentre ADAPT-Sepsis trial including 2760 adults across 41 UK critical care units. Patients were assigned to procalcitonin-guided, C-reactive protein-guided or standard care. Algorithm-generated recommendations (strong stop, suggest stop or standard care) were relayed to research staff and clinicians who remained blinded to group allocation. Adherence was defined as stopping biomarker sampling after advice. Advice timings, frequencies, adherence rates and reasons for non-adherence were recorded and analysed. Results Among 2760 patients, strong stop advice occurred earlier in those allocated to the procalcitonin-guided group compared with the C-reactive protein-guided group (mean difference -1.7 days, 95%CI -2.5 to -0.9, p < 0.001). C-reactive protein guidance generated a higher proportion of standard care advice (mean difference -9.1%, 95%CI -10.9% to -7.3%, p < 0.001). Overall advice adherence was greater in patients allocated to the C-reactive protein group than those allocated to the procalcitonin group (mean difference -6.8%, 95%CI -9.0 to -4.5, p < 0.001), driven by the higher proportion of standard care advice and later stronger stop advice with higher adherence (mean difference -14.3%, 95%CI -21.8 to -6.8, p < 0.001). Reasons for advice non-adherence included fixed-duration microbiology guidance, illness severity, continuing fever and elevation of routine inflammatory markers, which did not differ between groups. Discussion A C-reactive protein-guided discontinuation protocol achieved higher clinician adherence, probably because its recommendations aligned more closely with established prescribing norms. In contrast, procalcitonin guidance produced earlier and more frequent stop signals, offering greater potential to reduce antibiotic exposure but requiring clinicians to accept earlier discontinuation than usual practice.
引用
- Anaesthesia:Delivery and adherence of biomarker‐guided antibiotic treatment protocols in the ADAPT‐Sepsis clinical trial: an in‐trial descriptive process evaluation of daily procalcitonin‐ and C‐reactive protein‐guided protocols
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。